Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Short Interest Up 1,819.6% in June

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) saw a large increase in short interest in June. As of June 30th, there was short interest totaling 7,045 shares, an increase of 1,819.6% from the June 15th total of 367 shares. Based on an average daily trading volume, of 8,423 shares, the short-interest ratio is currently 0.8 days.

Clinuvel Pharmaceuticals Stock Up 1.1%

OTCMKTS CLVLY traded up $0.08 during trading hours on Friday, hitting $7.24. 1,042 shares of the company’s stock traded hands, compared to its average volume of 2,799. Clinuvel Pharmaceuticals has a 52-week low of $5.98 and a 52-week high of $9.00. The firm’s 50-day moving average is $6.86 and its 200-day moving average is $7.31.

Clinuvel Pharmaceuticals Company Profile

Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.

The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.